• TG Therapeutics (NasdaqCM:TGTX) raised its revenue guidance for 2026.
• The company cited strong performance of its multiple sclerosis drug Briumvi.
• It is also advancing clinical studies to test Briumvi in additional autoimmune indications.

TG Therapeutics focuses on treatments for autoimmune diseases, with Briumvi at the center of its current commercial efforts in multiple sclerosis. The updated 2026 revenue guidance highlights how Briumvi is shaping the company’s profile, as uptake trends inform management’s expectations. For you as an investor, this ties the company’s near term financial picture directly to the real world demand for this therapy.

The push into new autoimmune indications for Briumvi introduces additional clinical and regulatory milestones that could matter for the stock story around NasdaqCM:TGTX. As these studies progress, data readouts, filing decisions, and any label changes may become important markers for reassessing risk, potential market reach, and how concentrated the company is in one product.

Stay updated on the most important news stories for TG Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on TG Therapeutics.

For existing and potential shareholders, the guidance raise and strong Briumvi performance are a clear signal of how management currently views demand for its core multiple sclerosis product. The stock is up 29% over the past three months, which suggests many investors are already reacting to this stronger revenue outlook and the prospect of Briumvi playing a larger role in the MS market alongside competitors such as Roche’s Ocrevus and Novartis’s Kesimpta. The decision to fund multiple autoimmune studies around the same drug also shows TG Therapeutics is leaning into a focused product strategy rather than broad pipeline diversification, which concentrates both the opportunity and the risk profile in one franchise.

How This Fits Into The TG Therapeutics Narrative

• The higher 2026 revenue guidance and Briumvi-driven momentum line up with the existing narrative that sees Briumvi as the main growth catalyst, including potential upside from a planned subcutaneous version.
• At the same time, reliance on a single product keeps the earlier concerns about competition, pricing pressure, and payer preferences in focus, especially against larger rivals with broader portfolios.
• The push into additional autoimmune indications, beyond multiple sclerosis, adds another potential leg to the story that may not be fully captured in earlier commentary focused mainly on MS and funding conditions.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for TG Therapeutics to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Heavy dependence on Briumvi means any setback in clinical data, competition from other MS treatments, or reimbursement pressure could have an outsized impact on results.
• ⚠️ Analysts highlight at least one major risk tied to earnings quality, including a high level of non cash earnings, which may make reported profits harder to interpret.
• 🎁 Earnings are forecast by analysts to grow 15.91% per year, and recent guidance points to management confidence in the revenue trajectory around Briumvi.
• 🎁 The stock is described as trading at good value relative to peers and industry, with analysts also flagging strong recent earnings growth as a support for the investment case.

What To Watch Going Forward

From here, focus on whether Briumvi prescription trends continue to support the higher 2026 revenue guidance and how quickly TG Therapeutics can progress its additional autoimmune studies toward meaningful data readouts. Any updates on subcutaneous formulations, payer coverage decisions, or competitive moves from larger MS players will help you judge how durable the current momentum really is. It is also worth tracking how the company balances reinvestment in R&D with shareholder returns such as buybacks, because that mix will influence both growth potential and risk.

To stay up to date on how the latest news impacts the investment narrative for TG Therapeutics, head to the community page for TG Therapeutics to follow the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.